marcjohnson wrote:
are u slow dude? can u do 7.30 x 3, i will tell u dont worry, it's 21.90$:-) top hit last wednesday was 21.50$... see it? i know u dont. The rights offering 8 months ago let u acquire a truck load of shares (that u cannot buy at 8-9-10$ today) at the same price the new owners bought basically the company. This will trade 50-100$ next year.... see it? i know u dont.
and when u restructure and clear debt, u pay what is owed by CONTRACT. Ask AMF and TSX, all cleared 8 months ago by all.... only stupid crying whiny bittchs like are left...crying instead of making money:) It's your life though, enjoy it hahahaha see u in 2020.
AMF Concludes its Review of the Refinancing Transactions Completed by Liminal BioSciences in April 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Nov. 28, 2019 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ( "Liminal BioSciences" or the "Company" ), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, acknowledges the press release issued today by the Autorit des Marchs Financiers ("AMF") in which the AMF announced that after a thorough investigation, the AMF has determined that no violation or breach of securities regulation occurred in connection with the refinancing transactions completed by the Company in April 2019. The AMF is the regulatory and oversight body for Qubec's financial sector.
"We are pleased that the AMF has completed its review and concluded that it did not identify any violation or breach of securities regulation in the context of our refinancing transactions", stated Kenneth Galbraith, the Chief Executive Officer of Liminal BioSciences. "We have been cooperative and transparent with AMF throughout the review and look forward to focusing our efforts on developing and commercializing new medicines that may address serious unmet healthcare needs of patients around the world."
In April 2019, the Company completed a series of refinancing transactions, which were subject to the prior review and approval of the Toronto Stock Exchange. On November 18, 2019, the common shares of Liminal BioSciences commenced trading on the NASDAQ Global Market.
About Liminal BioSciences Inc.
Liminal BioSciences is an innovative biopharmaceutical company with a broad pipeline of small molecule therapeutics under development to treat unmet needs in patients with liver, respiratory and kidney disease, with a focus on rare or orphan diseases. Liminal BioSciences' research involves the study of several G-protein-coupled-receptors, GPR40, GPR84 and GPR120, known as free fatty acid receptors (FFAR's). These drug candidates have a novel mechanism of action as agonist ("stimulator") of GPR40 and GPR 120, and antagonist ("inhibitor") of GPR84. Our lead drug candidate, PBI-4050, is expected to enter Phase 3 clinical studies for the treatment of Alstrm Syndrome after further consultation and approval by the FDA and EMA. A second drug candidate, PBI-4547, is currently in a Phase 1 clinical study.